Search alternatives:
point decrease » point increase (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
point decrease » point increase (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
147081
-
147082
-
147083
-
147084
-
147085
-
147086
-
147087
-
147088
-
147089
-
147090
-
147091
-
147092
-
147093
-
147094
-
147095
-
147096
-
147097
-
147098
-
147099
-
147100
New advances in <i>DPYD</i> genotype and risk of severe toxicity under capecitabine - Fig 3
Published 2017“…<p>Distribution of pre-treatment plasma UH2/U ratio (A) and Uracil concentrations (B) for the 205 patients with validated phenotypic data, according to <i>DPYD</i> variants of interest: variant *2A (3 heterozygous patients), D949V (3 heterozygous patients), R592W (1 heterozygous patient), D342G (1 heterozygous patient), HapB3 (4 heterozygous patients), 166VV (3 homozygous patients) <i>vs</i> any other variations (185 patients) <i>vs</i> no variation (5 patients). …”